

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: JIA ET AL.)	
SERIAL NO.: 10/091,362)	EXAMINER: MELLER, M. V.
FILED: MARCH 1, 2002)	ART UNIT: 1655
TITLE: IDENTIFICATION OF FREE-B-RING FLAVONOIDS AS POTENT COX-2 INHIBITORS)	CONFIRMATION NO.: 7281

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application. In accordance with 37 C.F.R. §1.98(a)(3)(ii) the relevance of Nakagami (Aug. 1995) is set forth in the English abstract provided.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being submitted under 37 CFR § 1.97(d). This Statement is filed after a final action under 37 CFR § 1.113, after a notice of allowance under 37 CFR § 1.311, or after an action that otherwise closes prosecution on the merits, but before or simultaneously with the payment of the issue fee.

Certification under 37 CFR § 1.97(e)(1)

The undersigned hereby certified that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

The undersigned hereby authorizes the fee of \$180.00 to be charged to Deposit Account No. 19-5117, as well as any deficiency. It is believed that no other fees are due with this submission. If this is in error, please charge Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date May 14, 2007

/Rosemary Kellogg/
Rosemary Kellogg, #39,726
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
Telephone: (303) 268-0066
Facsimile: (303) 268-0065

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 2 of 1	ATTY. DOCKET NO. UNI.19	SERIAL NO. 10/091,362
	APPLICANT JIA ET AL.	
	FILING DATE March 1, 2002	GROUP 1655

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AK	WO 2003/0105030	06/05/2003	WO			
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AR	NAKAGAMI (August 22, 1995) abstract DATABASE WPI Week 199519 22 August 1995 (1995-08-22), Derwent Publications Ltd., London, GB; Class 954,page 2, AN 1995-325471 XP002418722 NAKAGAMI T; NAKAMURA T; TAMURA N: "Anti-complementary substance used as therapeutic agent - comprises gallic acid, methyl gallate, acetyl-salicylic acid, caffeic acid, catechin, epi-gallo-catechin gallate, myricetin, quercitrin and/or baicalein, or their salts" & JP 07 223941 A ((NIHA-N) NIPPON HAM KK)
	AS	
	AAA	
	AAB	
	AAD	
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and <u>not</u> considered. Include copy of this form with next communication to applicant.		